Meeting
2022 ASCO Annual Meeting
Patient-reported outcomes among males undergoing prostate cancer germline testing: Interim results from the Prostate Cancer Genetic Risk, Experience, and Support Study (PROGRESS) Registry.
Authors
Veda N. Giri
Departments of Medical Oncology, Cancer Biology, and Urology, Cancer Risk Assessment and Clinical Cancer Genetics Program, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
Veda N. Giri , Rebecca L. Hartman , Laura Gross , Scott W. Keith
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Prevention, Risk Reduction, and Hereditary Cancer
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Germline Genetic Testing
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 10595)
DOI
10.1200/JCO.2022.40.16_suppl.10595
Abstract #
10595
Poster Bd #
470
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Factors related to men’s experience with prostate cancer germline testing.
First Author: Veda N. Giri
Poster
2023 ASCO Genitourinary Cancers Symposium
Real world rates of genetic referrals and germline testing in patients with prostate adenocarcinoma at an academic cancer center in southern New Jersey.
First Author: Christopher Ambrogi
Poster
2023 ASCO Genitourinary Cancers Symposium
Awareness of genetic risk for prostate cancer (PCa) in men from families with germline mutations in DNA-repair genes.
First Author: Massimo Lazzeri
Poster
2021 Genitourinary Cancers Symposium
Barriers and facilitators of germline genetic evaluation for prostate cancer.
First Author: Stacy Loeb